Skip to content

Join our free Let’s Move Exercise Program! Accessible, expert-led virtual sessions to help you build strength and improve balance from home. REGISTER

SCAsource Article Summary

Developing therapeutically relevant biomarkers for SCA3

Written by Dr Hannah K Shorrock Edited by Dr Vitaliy V Bondar Measuring levels of polyQ ATXN3 proteins in cerebrospinal fluid and plasma distinguishes SCA3 patients from unaffected individuals For disease-modifying medicines or therapies to be approved for use in the clinic, the treatments must demonstrate success at meeting pre-set Read More…

Dieta rica em Creatina atrasa a SCA3 em camundongos

Escrito por Dr. Lauren R. Moore Editado por Dr.Larissa Nitschke. Inicialmente publicado em 5 de julho de 2019. Traduzido para o português por Ana Carolina Martins. A creatina, um suplemento alimentar comum tomado por atletas, atrasa sintomas e melhora o equilíbrio e força em camundongos com SCA3. Poderia um suplemento Read More…

Identifying serotonin receptors as a therapeutic target for SCA3

Written by Dr. Hannah K Shorrock Edited by Dr. Hayley McLoughlin A C. elegans model of SCA3 helps to identify the serotonin receptor agonist befiradol as a potential therapeutic for SCA3 To move toward treatments for ataxia patients, it is important to understand what cellular and molecular pathways are dysfunctional Read More…

Measuring neurodegeneration in spinocerebellar ataxias

Written by Dr Hannah K Shorrock Edited by Dr. Maria do Carmo Costa Neurofilament light chain predicts cerebellar atrophy across multiple types of spinocerebellar ataxia A team led by Alexandra Durr at the Paris Brain Institute identified that the levels of neurofilament light chain (NfL) protein are higher in SCA1, Read More…

Scientists develop a new approach to assessing Ataxia at home

Written by Ziyang Zhao Edited by Dr. Hayley McLoughlin A newly developed smartphone application will allow patients to assess ataxia at home. There’s an interesting problem in science that’s often overshadowed in the scientific community. It’s not as flashy or as newsworthy as most scientific headlines, like the eradication of Read More…

Identificación de moléculas aprobadas por la FDA para tratar SCA6

Escrito por la Dra. Hannah Shorrock Editado por la Dra. Larissa Nitschke. Publicado inicialmente en el 7 de mayo de 2021. Traducción al español fueron hechas por FEDAES y Carlos Barba. Pastor y sus colegas identifican pequeñas moléculas aprobadas por la FDA que reducen selectivamente la proteína tóxica expandida con poliglutamina Read More…

Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.